Germany · Delayed Price · Currency is EUR Fennec Pharmaceuticals Statistics
Total Valuation
FRA:RV41 has a market cap or net worth of EUR 241.23 million. The enterprise value is 239.01 million.
| Market Cap | 241.23M |
| Enterprise Value | 239.01M |
Important Dates
The last earnings date was Wednesday, November 19, 2025.
| Earnings Date | Nov 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 34.15M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.25% |
| Shares Change (QoQ) | +0.81% |
| Owned by Insiders (%) | 1.58% |
| Owned by Institutions (%) | 22.35% |
| Float | 23.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 13.19 |
| PS Ratio | 7.30 |
| PB Ratio | -63.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -40.41 |
| EV / Sales | 7.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.69
| Current Ratio | 4.69 |
| Quick Ratio | 4.21 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.66 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -5.39% |
| Return on Invested Capital (ROIC) | -13.94% |
| Return on Capital Employed (ROCE) | -11.82% |
| Revenue Per Employee | 1.03M |
| Profits Per Employee | -184,816 |
| Employee Count | 32 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.48 |
Taxes
In the past 12 months, FRA:RV41 has paid 311,090 in taxes.
| Income Tax | 311,090 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.43% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +21.43% |
| 50-Day Moving Average | 7.14 |
| 200-Day Moving Average | 6.64 |
| Relative Strength Index (RSI) | 52.07 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 9.75 |
Income Statement
In the last 12 months, FRA:RV41 had revenue of EUR 33.06 million and -5.91 million in losses. Loss per share was -0.22.
| Revenue | 33.06M |
| Gross Profit | 30.79M |
| Operating Income | -3.97M |
| Pretax Income | -5.60M |
| Net Income | -5.91M |
| EBITDA | -3.69M |
| EBIT | -3.97M |
| Loss Per Share | -0.22 |
Balance Sheet
The company has 18.71 million in cash and 16.52 million in debt, giving a net cash position of 2.19 million.
| Cash & Cash Equivalents | 18.71M |
| Total Debt | 16.52M |
| Net Cash | 2.19M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -3.83M |
| Book Value Per Share | -0.14 |
| Working Capital | 30.90M |
Cash Flow
| Operating Cash Flow | -6.81M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 93.12%, with operating and profit margins of -12.02% and -17.89%.
| Gross Margin | 93.12% |
| Operating Margin | -12.02% |
| Pretax Margin | -16.95% |
| Profit Margin | -17.89% |
| EBITDA Margin | -11.15% |
| EBIT Margin | -12.02% |
| FCF Margin | n/a |
Dividends & Yields
FRA:RV41 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.25% |
| Shareholder Yield | -1.25% |
| Earnings Yield | -2.45% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 5, 2014. It was a reverse split with a ratio of 0.3333333333.
| Last Split Date | Sep 5, 2014 |
| Split Type | Reverse |
| Split Ratio | 0.3333333333 |
Scores
FRA:RV41 has an Altman Z-Score of -2.94 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.94 |
| Piotroski F-Score | 1 |